This document provides an overview of the current standards and evolution of care for acute heart failure (AHF). It summarizes the use of biomarkers like natriuretic peptides and troponins in the diagnosis and risk stratification of AHF. It discusses the clinical considerations in stratifying AHF patients, including systolic blood pressure, worsening renal function, and the distribution of left ventricular ejection fraction. The document reviews current treatment options for AHF such as diuretics, vasodilators like nitroglycerin, and nesiritide based on clinical trials and guidelines.
Acute Heart Failure: Current Standards and Evolution of Care.2015
1. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Acute Heart Failure: Current
Standards and Evolution of Care
This program is supported by educational grants from Amgen
and Novartis.
2. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
About These Slides
Users are encouraged to use these slides in their own
noncommercial presentations, but we ask that content
and attribution not be changed. Users are asked to honor
this intent
These slides may not be published or posted online
without permission from Clinical Care Options
(email permissions@clinicaloptions.com)
Disclaimer
The materials published on the Clinical Care Options Web site reflect the views of the authors of the
CCO material, not those of Clinical Care Options, LLC, the CME providers, or the companies providing
educational grants. The materials may discuss uses and dosages for therapeutic products that have not
been approved by the United States Food and Drug Administration. A qualified healthcare professional
should be consulted before using any therapeutic product discussed. Readers should verify all information
and data before treating patients or using any therapies described in these materials.
3. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Faculty
Javed Butler, MD, MPH, MBA
Professor of Medicine
Chief of Cardiology
Division of Cardiology
Stony Brook University
Stony Brook, New York
G. Michael Felker, MD, MHS, FACC, FAHA
Professor of Medicine
Chief, Heart Failure Section
Division of Cardiology
Duke University
Durham, North Carolina
4. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Disclosures
Javed Butler, MD, MPH, MBA, has disclosed that that he has
received consulting fees from Amgen, Bayer, CardioCell,
Celladon, Novartis, Stealth Peptides, Trevena, Zensun, and ZS
Pharma and fees for non-CME/CE services from Novartis.
G. Michael Felker, MD, MHS, FACC, FAHA, has disclosed that
he has received consulting fees from Amgen, Bristol-Myers
Squibb, Celladon, Merck, Novartis, Relypsa, Roche
Diagnostics, Singulex, Stealth Peptides, and Trevena and funds
for research support from Amgen, Novartis, Otsuka, and Roche
Diagnostics.
5. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Patient Case: History
71-yr-old woman with history of hypertension, diabetes,
and obesity
No prior history of HF
Presents to emergency department with chief complaint of
breathlessness that has gradually progressed over 4 days;
has also noticed some peripheral edema
ROS: no chest pain + orthopnea
Current medicines at home: ASA, insulin, lisinopril
7. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Natriuretic Peptides in AHF Diagnosis
ACCF/AHA guidelines: measurement of BNP or NT-proBNP is useful in aiding a
diagnosis of ADHF[1]
Breathing Not Properly study: prospective study assessing the use of BNP in diagnosing
pts with HF (N = 1586)
1. Yancy CW, et al. J Am Coll Cardiol. 2013;62:e147-e239.
2. Maisel AS, et al. N Engl J Med. 2002;347:161-167.
Levels of BNP Differentiating Dyspnea due to
CHF vs Other Causes[2]
BNP (pg/mL) Accuracy
50 79
80 83
100 83
125 83
150 84
*Pts had a history of ventricular dysfunction.
1400
1200
1000
800
600
400
200
0
Dyspnea
due to CHF
(N = 744)
Dyspnea due
to Noncardiac
Causes*
(n = 72)
No CHF
(n = 770)
Median BNP Levels[2]
BNP(pg/mL)
8. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Additional Biomarkers in AHF Diagnosis
and Risk Stratification
Cardiac troponins[1]
– Markers of myocardial injury; increased circulating levels are associated
with poorer clinical outcomes and mortality
– ACCF/AHA: assessment recommended for additive risk stratification
Galectin-3 and sST2[1]
– Markers of myocardial fibrosis; prognostic for hospitalization and mortality
– ACCF/AHA: assessment recommended for additive risk stratification
Additional prognostic biomarkers[2]
– Cystatin C, AST, ALT
1. Yancy CW, et al. J Am Coll Cardiol. 2013;62:e147-e239.
2. Metra M, et al. J Am Coll Cardiol. 2013;61:196-206.
9. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Impact of Troponin Release on Survival in
AHF
Analysis of the ADHERE registry for pts hospitalized for ADHF who
had troponin measurements at initial evaluation
Peacock WF, et al. N Engl J Med. 2008;358:2117-2126.
0
2
4
6
8
2.0
2.7
3.4
5.3
> 0.20> 0.10-
0.20
> 0.04-
0.10
≤ 0.04
Troponin I Quartile
9534932310,36711,090Pts, n
In-HospitalMortality(%)
11. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Stratification of Pts With AHF
Yancy CW, et al. J Am Coll Cardiol. 2013;62:e147-e239.
No
Warm and Dry
Yes
Warm and Wet
Cold and Dry Cold and WetYes
No
Congestion at Rest?
(eg, orthopnea, elevated jugular venous pressure,
pulmonary rales, S3 gallop, edema)
LowPerfusionatRest?
(eg,narrowpulsepressure,
coolextremities,hypotension)
12. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Systolic Blood Pressure at Admission in
Pts Hospitalized for AHF
Data from the OPTIMIZE-
HF registry (48,612 pts)
~ 75% pts with SBP
≥ 120 mm Hg
Gheorghiade M, et al. JAMA. 2006;296:2217-2226.
24.9% 25.2%
24.9% 24.9%
SBP < 120 mm Hg
SBP 140-161 mm Hg
SBP 120-139 mm Hg
SBP > 161 mm Hg
13. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Precipitating Causes of AHF Are Poorly
Understood
Increased sodium diet
Myocardial ischemia
Mild respiratory or urinary tract infection
Arrhythmia (eg, atrial fibrillation )
Poorly controlled hypertension
Pneumonia
Noncompliance with chronic medications
Yancy CW, et al. J Am Coll Cardiol. 2013;62:e147-e239.
14. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
ACCF/AHA Definitions of HFrEF and
HFpEF
Yancy CW, et al. J Am Coll Cardiol. 2013;62:e147-e239.
Classification EF, % Description
I. HFrEF ≤ 40 Also referred to as systolic HF. Randomized controlled trials have
mainly enrolled pts with HFrEF, and it is only in these pts that
efficacious therapies have been demonstrated to date
II. HFpEF ≥ 50 Also referred to as diastolic HF. Several different criteria have been
used to further define HFpEF. The diagnosis of HFpEF is
challenging because it is largely one of excluding other potential
noncardiac causes of symptoms suggestive of HF. To date,
efficacious therapies have not been identified
a. HFpEF,
borderline
41-49 These pts fall into a borderline or intermediate group. Their
characteristics, treatment patterns, and outcomes appear
similar to those of pts with HFpEF
b. HFpEF,
improved
> 40 It has been recognized that a subset of pts with HFpEF previously
had HFrEF. These pts with improvement or recovery in EF may be
clinically distinct from those with persistently preserved or reduced
EF. Further research is needed to better characterize these pts
15. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Distribution of LVEF in AHF Pts
LVEF (%)
0-
5
6-
10
11-
15
16-
20
21-
25
26-
30
31-
35
36-
40
41-
45
46-
50
51-
55
56-
60
61-
65
66-
70
71-
75
76-
80
81-
85
86-
90
91-
95
96-
100
Pts(n)
Documented LVEF Measured Prior to or During Hospitalization
HFrEF HFpEF
Fonarow GC, et al. J Am Coll Cardiol. 2007;50:768-777.
5000
4000
3000
2000
1000
0
16. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
ADHERE CART Analysis: In-Hospital
Mortality
Assessed 33,046 pts
hospitalized with AHF
Pts could be classified as
having a low, intermediate, or
high risk of in-hospital mortality
based on admission levels of:
– BUN
– SBP
– Serum creatinine
Pats with lowest mortality risk
(2.14% crude mortality
[445/20,834]):
– BUN < 43 mg/dL
– SBP ≥ 115 mm Hg
Pts with highest mortality risk
(21.94% crude mortality
[136/620]):
– BUN ≥ 43 mg/dL
– SBP < 115 mm Hg
– Serum creatinine ≥ 2.75 mg/dL
Fonarow G, et al. JAMA. 2005;293:572-580.
17. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Worsening Renal Function as a
Prognostic Indicator for Pts With AHF
Study assessed 1681 pts 65 yrs of age or older
Krumholz H, et al. Am J Cardiol. 2000;85:1110-1113.
Outcome
RF Not Worse
(n = 1212)
RF Worse
(n = 469)
OR (95% CI)
In-hospital mortality, % 3 7 2.7 (1.6-4.6)
30-day mortality, % 6 10 1.9 (1.3-2.8)
6-mo mortality, % 19 25 1.6 (1.2-2.1)
Length of hospital stay,
days
6.93 9.14
18. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Patient Case: Initial Assessment
Exam
– BP 174/93, HR 90,
BMI 39
– JVP difficult to assess
due to body habitus
– RRR: no murmurs or
gallops
– Basilar rales
– 2+ lower extremity edema
to knees
Labs and Imaging
– Serum creatinine
1.8 mg/dL
– Troponin levels not
elevated
– ECG shows NSR and
narrow QRS, with
nonspecific ST-T wave
changes
– CXR shows cardiomegaly
with increased interstitial
markings
20. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Diuretics in Hospitalized Pts
ACCF/AHA guidelines (Class I, LOE B recommendation)
– Pts with HF admitted with evidence of significant fluid
overload should be promptly treated with IV loop diuretics to
reduce morbidity
– If pts are already receiving loop diuretic therapy, the initial IV
dose should equal or exceed their chronic oral daily dose
and should be given as either intermittent boluses or
continuous infusion. Urine output and signs and symptoms
of congestion should be serially assessed, and the diuretic
dose should be adjusted accordingly to relieve symptoms,
reduce volume excess, and avoid hypotension
Yancy CW, et al. J Am Coll Cardiol. 2013;62:e147-e239.
21. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
DOSE: Loop Diuretics in AHF
Double-blind, randomized trial of low- vs high-dose IV furosemide via bolus or
continuous infusion in AHF pts (N = 308)
Coprimary endpoints: pts’ global assessment of symptoms and change in
serum creatinine level from baseline to 72 hrs
0.08
0.10
ChangeinCreatinine(mg/dL)
Low Dose
P = .21
Felker GM, et al. N Engl J Med. 2011;364:797-805.
0.05
0
0.04
100
80
60
40
20
0
GlobalAssessmentof
Symptoms(GlobalVASScore)
0 10 20 30 40 50 60 70
Hrs
AUC with low-dose strategy: 4171 ± 1436
AUC with high-dose strategy: 4430 ± 1401
P = .06
High dose Low dose
High Dose
22. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Vasodilators in AHF
ACCF/AHA guidelines (Class IIb, LOE A recommendation)
– If symptomatic hypotension is absent, IV nitroglycerin,
nitroprusside or nesiritide may be considered an adjuvant to
diuretic therapy for relief of dyspnea in pts admitted with
acutely decompensated HF
Yancy CW, et al. J Am Coll Cardiol. 2013;62:e147-e239.
23. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
8.69.5
10
ASCEND-HF: 6- and 24-Hr Dyspnea and
Mortality/Rehospitalization
Randomized, placebo-controlled phase III study of nesiritide for 24-168 hrs in
hospitalized pts with AHF (N = 7141)
O’Connor CM, et al. N Engl J Med. 2011;365:32-43.
12
10
8
6
4
2
0
10.1
4.0
9.4
6.1
3.6
6.0
Death or
Rehospitalization
for HF
Death Rehospitalization
for HF
Death From Any Cause or
Rehospitalization for HF at 30 Days
-0.4
(-1.3 to 0.5)
-0.7
(-2.1 to 0.7)
-0.1
(-1.2 to 1.0)
Percentage point
difference (95% CI)
P = .31
HR: 0.93
(95% CI: 0.8-1.08)
Placebo Nesiritide
42.1
13.4
28.7
34.1
21.7
44.5
15.0
29.5
32.8
20.3
70
60
50
40
30
20
0
10
20
30
40
50
60
Placebo
(n = 3444)
Nesiritide
(n = 3416)
66.1
27.5
38.6
22.1
68.2
30.4
37.8
21.2
Placebo
(n = 3398)
Nesiritide
(n = 3371)
6 Hrs
P = .03
24 Hrs
P = .007
Self-Assessed Change in Dyspnea
Markedly better
Moderately better
Minimally better
No change
Minimally worse
Moderately worse
Markedly worse
Pts(%)
Pts(%)
24. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
1-yr mortality rates did not change
over the last decade[2]
Nearly 1 in 4 AHF pts
readmitted within 30 days[1]
1. Dharmarajan K, et al. JAMA. 2013;309:355-363. 2. Chen J, et al. JAMA. 2011;306:1669-1678.
Postdischarge Outcomes in AHF
30
0
5
25
10
20
15
PtsReadmitted(%)
Days Following
Hospital Discharge
20100 30 40
100
0
20
Risk-Adjusted
MortalityRate*(%)
Yr
2003
2002
1999
2001
2005
2000
2008
2007
40
2006
2004
80
60
*Risk-adjusted rates relative to 1999.
25. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Inotropic Support
ACCF/AHA guidelines (Class IIb, LOE B recommendation)
– Short-term, continuous IV inotropic support may be
reasonable in those hospitalized pts presenting with
documented severe systolic dysfunction who present with
low blood pressure and significantly depressed cardiac
output to maintain systemic perfusion and preserve end-
organ performance
Yancy CW, et al. J Am Coll Cardiol. 2013;62:e147-e239.
26. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
AERate(%)
Treatment Failure
From AE (48 hrs)
Sustained
Hypotension
Acute MI Mortality
Milrinone
Placebo
Afib
P < .001
P < .001
P = .18
P = .004 P = .19
12.6
2.1
10.7
3.2
1.5
0.4
4.6
1.5
3.8
2.3
0
5
10
15
20
OPTIME-CHF: In-Hospital AEs
Randomized, double-blind, placebo-controlled trial of short-term IV milrinone
in pts hospitalized due to chronic heart failure exacerbation (N = 951)
Cuffe MS, et al. JAMA. 2002;287:1541-1547.
27. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Ultrafiltration
ACCF/AHA guidelines
– Ultrafiltration may be considered for pts with obvious volume
overload to alleviate congestive symptoms and fluid weight
(Class IIb, LOE B recommendation)
– Ultrafiltration may be considered for pts with refractory
congestion not responding to medical therapy (Class IIb,
LOE C recommendation)
Yancy CW, et al. J Am Coll Cardiol. 2013;62:e147-e239.
28. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Weight
Gain
(lb)
CARRESS: Change in Creatinine and
Weight at 96 Hrs
Randomized trial of ultrafiltration vs stepped pharmacologic therapy
in pts with AHF, worsened renal function, and persistent congestion
(N = 188)
Bart BA, et al. N Engl J Med. 2012;367:2296-2304.
P = .003
Weight
Loss
(lb)
Creatinine Increase
(mg/dL)
Creatinine
Decrease (mg/dL)
1.0
0.8
0.6
0.4
0.2
0
-0.2
-0.4
-0.6
-0.8
0-2-4-6-8-10-12-14-16-18-20
Ultrafiltration
(n = 92)
Pharmacologic
therapy
(n = 94)
29. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
CARRESS: Change in Creatinine Over 60
Days
Bart BA, et al. N Engl J Med. 2012;367:2296-2304.
0.30
0.20
0.10
0
-0.10
-0.20
-0.30
-0.40
-0.50
P = .35
72
Hrs
48
Hrs
24
Hrs
96
Hrs
7
Days
30
Days
60
Days
Serum Creatinine
P = .048 P = .007
P = .002
P = .50
P = .17
P = .03
MeanCreatinineChangeFrom
Baseline(mg/dL)
Pharmacologic therapy
Ultrafiltration
30. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Patient Case: Treatment
Echocardiogram shows EF 30% with global hypokinesis,
mild MR/TR
Treated with IV furosemide and continuation of oral
medications
Responds with brisk diuresis and improvement in
symptoms
Pt is discharged with improved symptoms on hospital
Day 6
Added carvedilol and spirolactone to outpatient regimen
32. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Ularitide
Natriuretic peptide with
vasodilating and diuretic
properties
Previously assessed in the
randomized, double-blind,
placebo-controlled phase II
SIRIUS trial (N = 221)[1]
– Standard of care + IV ularitide
improved dyspnea and
decreased PWCP vs placebo in
hospitalized pts with AHF
TRUE-AHF[2]
– Multicenter, randomized,
double-blind, placebo-
controlled phase III study
– Pts will receive IV ularitide or
placebo for 48 hrs within 12 hrs
of ED admission
– Pts will have persisting dyspnea
at rest despite standard therapy
for AHF
Primary endpoints
– Clinical composite including
dyspnea relief, worsening of
heart failure, and all-cause
mortality
– CV mortality1. Mitrovic V, et al. Eur Heart J. 2006;27:2823-2832.
2. Clinicaltrials.gov. NCT01661634.
33. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
1. Stewart DR, et al. J Clin Endocrinol Metab. 1990;70:1771-1773. 2. Szlachter BN, et al. Obstet Gynecol.
1982;59:167-170. 3. Teerlink JR, et al. Lancet. 2013;381:29-39.
Serelaxin
Relaxin: naturally occurring peptide; normal hormone of pregnancy[1,2]
Benign safety profile
RELAX-AHF[3]
– Randomized, placebo-controlled trial of standard of care + 48 hrs IV
serelaxin or placebo in hospitalized pts w/AHF (N = 1161)
– Serelaxin treatment improved dyspnea, as measured by VAS AUC (19.4%
increase in AUC with serelaxin from baseline through Day 5 vs placebo)
34. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
RELAX-AHF: CV Death Through Day 180
0
14
12
10
8
6
4
2
CVDeath(ITT)(%)
0 14 30 60 90 120 150 180
HR: 0.63 (95% CI: 0.41-0.96; P = .028)
55 (9.6)
35 (6.1)
Placebo (n = 580)
Serelaxin (n = 581)
Events,
n (%)
NNT = 29
Days
Teerlink JR, et al. Lancet. 2013;381:29-39.
35. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
120
160
40
80
140
180
20
60
100
0
Prognostic Indicators of 180-Day Mortality
Metra M, et al. J Am Coll Cardiol. 2013;61:196-206.
< 30% decrease
≥ 30% decrease
NT-proBNP
< 22 nmo/L Increase (0.3 mg/L)
≥ 22 nmo/L Increase (0.3 mg/L)
Cystatin C
CumulativeRisk
Study Day
< 20% increase
≥ 20% increase
ALT
CumulativeRisk
< 20% increase
≥ 20% increase
Troponin T
0
No WHF to Day 5
WHF to Day 5
Worsening Heart Failure
0
< 20% increase
≥ 20% increase
AST
0.47 (0.31-0.69)
P = .0001
2.10 (1.38-3.20)
P = .0004
1.96 (1.13-3.40)
P = .0152
1.80 (1.16-2.78)
P = .0076
1.66 (0.92-3.00)
P = .0987
1.90 (1.11-3.22)
P = .0164
120
160
40
80
140
180
20
60
100
0
120
160
40
80
140
180
20
60
100
0
120
160
40
80
140
180
20
60
100
0
0
0.20
0.15
0.10
0.05
0
120
160
40
80
140
180
20
60
100
0
0.20
0.15
0.10
0.05
0
120
160
40
80
140
180
20
60
100
0
Study Day
0
Study Day
36. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Omecamtiv Mecarbil
Selective activator of cardiac myosin
In a placebo-controlled study in healthy volunteers
(N = 34), 6-hr infusions of omecamtiv mecarbil
– Prolonged systole ejection time
– Increased stroke volume
– Increased fractional shortening
– Increased ejection fraction
Teerlink JR, et al. Lancet. 2011;378:667-675.
37. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
ATOMIC-AHF
Randomized, placebo-controlled phase II study of omecamtiv mecarbil for treating AHF
(N = 606)
3 sequential dose-escalation cohorts received 48-hr IV OM infusion (cohorts 1-3
targeted median OM plasma concentrations of 115, 230, and 310 ng/mL, respectively)
Primary endpoint: dyspnea symptom response (7-point Likert scale) through 48 hrs
Teerlink JR, et al. ESC 2013. Abstract 709.
Response Rate
Ratio* (95% CI)
Cohort 1 1.03 (0.79-1.35)
Cohort 2 1.15 (0.90-1.47)
Cohort 3 1.23 (0.97-1.55)
Pooled
Placebo
(n = 303)
OM
Cohort 1
(n = 103)
OM
Cohort 2
(n = 99)
OM
Cohort 3
(n = 101)
*Relative to pooled placebo.
100
0
41 42
47 51
Overall P = .33
DyspneaResponseRate
(%Responders)
20
40
60
80
38. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Postdischarge Outcomes in AHF
Nearly 1 in 4 AHF pts readmitted within 30 days
Dharmarajan K, et al. JAMA. 2013;309:355-363.
30
0
5
25
10
20
15
PtsReadmitted(%)
Days Following
Hospital Discharge
20100 30 40
39. clinicaloptions.com/cardiology
Acute Heart Failure: Current Standards and Evolution of Care
Go Online for Additional
Discussion of Acute Heart Failure
CME-certified video
Downloadable PowerPoint slideset
ClinicalThought commentary
clinicaloptions.com/cardiology
Editor's Notes
This slide lists the faculty who were involved in the production of these slides.
This slide lists the disclosure information of the faculty and staff involved in the development of these slides.
ASA, acetylsalicylic acid; HF, heart failure; ROS, review of systems.
ACCF, American College of Cardiology Foundation; ADHF, acute decompensated heart failure; AHA, American Heart Association; AHF, acute heart failure; BNP, B-type natriuretic peptide; CHF, congestive heart failure; NT-proBNP, amino-terminal pro-B-type natriuretic peptide.
ACCF, American College of Cardiology Foundation; AHA, American Heart Association; AHF, acute heart failure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BNP, B-type natriuretic peptide; NT-proBNP, amino-terminal pro-B-type natriuretic peptide.
ACCF, American College of Cardiology Foundation; ADHF, acute decompensated heart failure; AHA, American Heart Association; AHF, acute heart failure; BNP, B-type natriuretic peptide; NT-proBNP, amino-terminal pro-B-type natriuretic peptide.
ACCF, American College of Cardiology Foundation; AHA, American Heart Association; EF, ejection fraction; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
AHF, acute heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction.
BMI, body mass index; BP, blood pressure; CXR, chest x-ray; ECG, electrocardiogram; HR, heart rate; JVP, jugular venous pressure; NSR, normal sinus rhythm; RRR, regular rate and rhythm.
ACCF, American College of Cardiology Foundation; AHA, American Heart Association; HF, heart failure; IV, intravenous; LOE, level of evidence.
AHF, acute heart failure; AUC, area under the curve; IV, intravenous; VAS, visual analogue scale.
ACCF, American College of Cardiology Foundation; AHA, American Heart Association; AHF, acute heart failure; HF, heart failure; IV, intravenous; LOE, level of evidence.
AHF, acute heart failure; HF, heart failure.
AHF, acute heart failure.
ACCF, American College of Cardiology Foundation; AHA, American Heart Association; IV, intravenous; LOE, level of evidence.